Dr. Adeel Khan

So meaning even if they're not replicating, you can, you can basically homogenize, it's called homogenization, which is basically like, you know, you're blending, you know, how you, you know, you blend like fruit to get like the, the pulp out and the juice. It's like taking the juice basically of tissue and that's the exosome. So you can do that now with any tissue.

So meaning even if they're not replicating, you can, you can basically homogenize, it's called homogenization, which is basically like, you know, you're blending, you know, how you, you know, you blend like fruit to get like the, the pulp out and the juice. It's like taking the juice basically of tissue and that's the exosome. So you can do that now with any tissue.

So for example, there's people working on natural killer exosomes, dendritic cell exosomes, exosomes from liver, from muscle. So there's so many interesting exosome products being worked at. There's 290 or 281 patterns or something like that on exosomes in the last like couple of years. So that can tell you the scale.

So for example, there's people working on natural killer exosomes, dendritic cell exosomes, exosomes from liver, from muscle. So there's so many interesting exosome products being worked at. There's 290 or 281 patterns or something like that on exosomes in the last like couple of years. So that can tell you the scale.

Oh yeah. So that tells you the scale though, 200 over 200 patents on just exosomes alone in the last couple of years. So that tells you the scale and the magnitude of research that's happening right now.

Oh yeah. So that tells you the scale though, 200 over 200 patents on just exosomes alone in the last couple of years. So that tells you the scale and the magnitude of research that's happening right now.

Exactly. Yeah. Yeah. So yeah, a few things. First thing I would say, just because you touched on a little bit, was there's a lot of politics limiting regenerative medicine's ability to really get mainstream in US.

Exactly. Yeah. Yeah. So yeah, a few things. First thing I would say, just because you touched on a little bit, was there's a lot of politics limiting regenerative medicine's ability to really get mainstream in US.

And interestingly, Japan has the opposite politics, which is that because of Professor Yamanaka, they spent $8 billion of taxpayer money on regenerative medicine, and they have lobbyists for regenerative medicine. So it's very different. environment that's actually favorable for regenerative medicine.

And interestingly, Japan has the opposite politics, which is that because of Professor Yamanaka, they spent $8 billion of taxpayer money on regenerative medicine, and they have lobbyists for regenerative medicine. So it's very different. environment that's actually favorable for regenerative medicine.

And unfortunately, the US has taken a really archaic stance to the point where they regulate exosomes, which is an a cellular product, meaning it doesn't have any cells, like you said, no DNA material, and therefore we know it's very safe. They're just signals that stay in the body for minutes to hours, and then they're more or less they're gone.

And unfortunately, the US has taken a really archaic stance to the point where they regulate exosomes, which is an a cellular product, meaning it doesn't have any cells, like you said, no DNA material, and therefore we know it's very safe. They're just signals that stay in the body for minutes to hours, and then they're more or less they're gone.

But they help to change the micro environment and help to change the functioning of cells. And so the safety is so high of exosomes, but FDA has decided to regulate it like a drug. And so therefore an FDA has still not approved any drug or any exosome products.

But they help to change the micro environment and help to change the functioning of cells. And so the safety is so high of exosomes, but FDA has decided to regulate it like a drug. And so therefore an FDA has still not approved any drug or any exosome products.

So technically, I mean, obviously there's so many clinics offering it, which is very interesting, but technically none of them are FDA approved. So it's just something to understand the regulatory environment. I don't agree with it, but that's the world we live in. And that's why people have to travel offshore, unfortunately. And I think that's going to be the way it is for the next few years.

So technically, I mean, obviously there's so many clinics offering it, which is very interesting, but technically none of them are FDA approved. So it's just something to understand the regulatory environment. I don't agree with it, but that's the world we live in. And that's why people have to travel offshore, unfortunately. And I think that's going to be the way it is for the next few years.

It'll take a while before even someone like us gets FDA approval for the new exosomes. It takes seven years, five to seven years. You have to go through the phase one, the phase two, the phase three, the post-market. You have to go through all that. And even then, you may not get FDA approval. And so they really made it difficult for regenerative medicine, which doesn't make sense.

It'll take a while before even someone like us gets FDA approval for the new exosomes. It takes seven years, five to seven years. You have to go through the phase one, the phase two, the phase three, the post-market. You have to go through all that. And even then, you may not get FDA approval. And so they really made it difficult for regenerative medicine, which doesn't make sense.

Oh, yeah, exactly. U.S. is being left behind, basically.

Oh, yeah, exactly. U.S. is being left behind, basically.